The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke
Open accessAbstract
tPA is a clot-buster used to treat stroke, but if it's given too late after stroke onset, it can cause complications like hemorrhage. Daniel Lawrence and his colleagues show that a US Food and Drug Administration–approved kinase inhibitor, Gleevec, can prevent this side effect, thereby extending tPA's therapeutic window. Thrombolytic treatment of ischemic stroke with tissue plasminogen activator (tPA) is markedly limited owing to concerns about hemorrhagic complications and the requirement that tPA be administered within 3 h of symptoms. Here we report that tPA activation of latent platelet-derived growth factor-CC (PDGF-CC) may explain these limitations. Intraventricular injection of tPA or active PDGF-CC, in the absence of ischemia, leads to significant increases in cerebrovascular permeability. In contrast, co-injection of neutralizing antibodies to PDGF-CC with tPA blocks this increased permeability, indicating that PDGF-CC is a downstream substrate of tPA within the neurovascular unit. These effects are mediated through activation of PDGF-α receptors (PDGFR-α) on perivascular astrocytes, and treatment of mice with the PDGFR-α antagonist imatinib after ischemic stroke reduces both cerebrovascular permeability and hemorrhagic complications associated with late administration of thrombolytic tPA. These data demonstrate that PDGF signaling regulates blood-brain barrier permeability and suggest potential new strategies for stroke treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Writing Group Members, Thom, T., Haase, N., Rosamond, W., Howard, V. J., Rumsfeld, J., Manolio, T., Zheng, Z.-J., Flegal, K., O’Donnell, C., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.171600 · Cited by 3,451
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Larrue, V., von Kummer, R., Müller, A., & Bluhmki, E. (2001) · Stroke · doi:10.1161/01.str.32.2.438 · Cited by 1,006
Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic Stroke
The NINDS t-PA Stroke Study Group (1997) · Stroke · doi:10.1161/01.str.28.11.2109 · Cited by 880
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling
Nicole, O., Docagne, F., Ali, C., Margaill, I., Carmeliet, P., MacKenzie, E. T., Vivien, D., & Buisson, A. (2001) · Nature Medicine · doi:10.1038/83358 · Cited by 735
Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator
Tsirka, S. E., Gualandris, A., Amaral, D. G., & Strickland, S. (1995) · Nature · doi:10.1038/377340a0 · Cited by 663
Wang, Y. F., Tsirka, S. E., Strickland, S., Stieg, P. E., Soriano, S. G., & Lipton, S. A. (1998) · Nature Medicine · doi:10.1038/nm0298-228 · Cited by 630
PDGF-C is a new protease-activated ligand for the PDGF α-receptor
Li, X., Pontén, A., Aase, K., Karlsson, L., Abramsson, A., Uutela, M., Bäckström, G., Hellström, M., Boström, H., Li, H., et al. (2000) · Nature Cell Biology · doi:10.1038/35010579 · Cited by 623
Self-citationTwo Classes of PDGF Receptor Eecognize Different Isoforms of PDGF
Hart, C. E., Forstrom, J. W., Kelly, J. D., Seifert, R. A., Smith, R. A., Ross, R., Murray, M. J., & Bowen-Pope, D. F. (1988) · Science · doi:10.1126/science.2836952 · Cited by 580
Cited by
Pericytes regulate the blood–brain barrier
Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K., et al. (2010) · Nature · doi:10.1038/nature09522 · Cited by 2,843
Self-citationKang, S. H., Fukaya, M., Yang, J. K., Rothstein, J. D., & Bergles, D. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.009 · Cited by 787
Hemorrhagic Transformation after Ischemic Stroke in Animals and Humans
Jickling, G. C., Liu, D., Stamova, B., Ander, B. P., Zhan, X., Lu, A., & Sharp, F. R. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.203 · Cited by 547
Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke
Lakhan, S. E., Kirchgessner, A., Tepper, D., & Leonard, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00032 · Cited by 384
The PDGF/PDGFR pathway as a drug target
Papadopoulos, N., & Lennartsson, J. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.007 · Cited by 283
Metadata
- Authors
- Su, E. J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J., Andrae, J., Gao, Y., Pietras, K., Mann, K., Yepes, M., Strickland, D. K., Betsholtz, C., Eriksson, U., & Lawrence, D. A.
- Venue
- Nature Medicine
- Published
- 2008-06-22
- Volume
- 14
- Issue
- 7
- Pages
- 731-737
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1998907224
- Cited by
- 468
- References
- 43
- FWCI
- 15.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. https://app.cochat.ai/papers/10.1038/nm1787
- The paper
- Su, E. J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J., Andrae, J., Gao, Y., Pietras, K., Mann, K., Yepes, M., Strickland, D. K., Betsholtz, C., Eriksson, U., & Lawrence, D. A. (2008). Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nature Medicine. https://doi.org/10.1038/nm1787
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.